Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 21:57:40 - browse：72837

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Hospitals look to new technology to keep health care workers safe

WSS

A daunting task: navigating dual Medicare, Medicaid eligibility

Let's speed up science by embracing open access publishing

BMI, flaws aside, is found to be useful estimate of body fat in youth

Anthos stroke drug appears safer than common blood thinner

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

Wikipedia

focus

Walensky prepares to leave CDC — and Congress — behind

Anthos stroke drug appears safer than common blood thinner

Trump demands the U.S. pay no more for drugs than other countries … again

How to increase colonoscopy rates? Looks like an AI can help

Medicare details structure of new drug price negotiation program

Let's speed up science by embracing open access publishing

Medical leaders decry Supreme Court decision on affirmative action

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Medical records are filled with copy

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

knowledge

Ionis drug prevents swelling attacks due to hereditary angioedema

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Kaiser's Risant Health gobbled up Geisinger. Who is next?

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Poor hospice wound care hurts patients and families

entertainment

leisure time

Wikipedia

explore